Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

Inclusion Criteria: -Histologically or cytologically confirmed unresectable locally advanced NSCLC with progressed or recurred after no more than four previous docetaxel-free chemotherapy regimens, or unresectable locally advanced or metastatic SCCHN or recurred after previous docetaxel-free chemotherapy regimens Exclusion Criteria: 1. Women who are nursing or pregnant during the study period; 2. Patients with carcinoid tumors, small-cell carcinoma of the lung; 3. A history of another malignancy within the last five years (except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the uterine cervix); 4. Any other morbidity or situation with contraindications for chemotherapy (e.g. active infection, myocardial infarction in the preceding 6 months); 5. Neutrophil counts \< 1,500 cells/mm3; 6. A history of hypersensitivity to docetaxel or cisplatin; 7. Symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias; 8. Subjects have active hepatitis; 9. Subjects are known positive for Human Immunodeficiency Virus (HIV); 10. Any condition judged by investigator, participates the study will jeopardize patient's wellbeing